<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979975</url>
  </required_header>
  <id_info>
    <org_study_id>UBP-A229-HSV</org_study_id>
    <nct_id>NCT04979975</nct_id>
  </id_info>
  <brief_title>Evaluating Safety and Efficacy of Repeat Doses of UB-621in Adult Patients With Recurrent Genital Herpes</brief_title>
  <official_title>A Randomized, Single-blind, Placebo-control, Parallel, Phase II Trial to Evaluate the Safety and Efficacy of UB-621 in Adults With Recurrent Genital HSV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UBP Greater China (Shanghai) Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UBP Greater China (Shanghai) Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of repeat-dose UB-621 for the recurrent genital HSV-2 infection To&#xD;
      evaluate the safety and tolerance of repeat-dose UB-621 for the recurrent HSV-2 infection To&#xD;
      evaluate the pharmacokinetics of repeat-dose UB-621 in RGH patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2022</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first recurrence</measure>
    <time_frame>26 weeks</time_frame>
    <description>Time to first recurrence episode after experimental drug administration as reported by patient and verified by investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with episodes</measure>
    <time_frame>26 weeks</time_frame>
    <description>Proportion of subjects with episodes is calculated as the number of subjects with episodes divided by the number of total subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lesion rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>Lesion rate is calculated as the number of days with lesion divided by the number of study days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of recurrent lesions</measure>
    <time_frame>26 weeks</time_frame>
    <description>Duration of recurrent lesions is calculated as consecutive days with lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate</measure>
    <time_frame>26 weeks</time_frame>
    <description>Recurrence rate is defined as number of recurrences divided by the total number of study days.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>HSV-2 shedding rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Viral shedding rate is defined as the number of positive anogenital swabs divided by total number of swabs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical and Subclinical HSV-2 Shedding Rates</measure>
    <time_frame>12 weeks</time_frame>
    <description>Daily record of subject self-assessment of genital lesions in subject diary in addition to anogenital swabs collected daily from subjects during the follow-up periods will be used to evaluate the clinical (lesional) and subclinical (non-lesional) HSV-2 shedding rates.</description>
  </other_outcome>
  <other_outcome>
    <measure>Rate of HSV-2 Shedding Episodes</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of HSV-2 shedding episodes is the number of onsets of shedding episodes divided by the total number of days with swabs collected. Shedding episodes are defined as consecutive HSV-2 positive swab results including no more than 1 consecutive negative result or missed swab. The episodes are preceded and followed by 2 consecutive negative swab results.</description>
  </other_outcome>
  <other_outcome>
    <measure>HSV-2 viral load</measure>
    <time_frame>12 weeks</time_frame>
    <description>Anogenital swab samples collected from subjects during follow-up period will be used to quantify HSV-2 DNA copies.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Recurrent Genital Herpes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo matching UB-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-621 low-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low-dose of UB-621</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-621 high-dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high-dose of UB-621</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBO- placebo matching to UB-621</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-621 low-dose</intervention_name>
    <description>fully human anti-HSV mAb</description>
    <arm_group_label>UB-621 low-dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-621 high-dose</intervention_name>
    <description>fully human anti-HSV mAb</description>
    <arm_group_label>UB-621 high-dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≧18 years at the time of signing ICF&#xD;
&#xD;
          2. HSV-2 seropositive when screening&#xD;
&#xD;
          3. A history of recurrent genital herpes and experience 6-12 episodes in the past year&#xD;
&#xD;
          4. Negative result of the HIV assay&#xD;
&#xD;
          5. In baseline period, subject have to present at the site within 72 hours after the&#xD;
             occurrence of new lesions&#xD;
&#xD;
          6. Keep daily diary during the study period&#xD;
&#xD;
          7. Female subjects: negative serum β-HCG at screening and no beast-feeding.&#xD;
&#xD;
          8. Use contraception during study participation&#xD;
&#xD;
          9. Understanding and willing to fully comply with study interventions and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any medical conditions that may interfere the assessment of UB-621efficacy, or any&#xD;
             medical conditions that may present symptoms in the anogenital regions (such as&#xD;
             syphilis, genital warts).&#xD;
&#xD;
          2. History of malignancy, diabetes, auto-immune diseases or immunodificiency diseases.&#xD;
&#xD;
          3. Use of systemic steroids or immunomodulators within 30 days prior to the screening&#xD;
&#xD;
          4. Participating any clinical trials within 30 days prior to the screening, or within 5&#xD;
             half-life of any investigational drugs, take the longer.&#xD;
&#xD;
          5. Vaccination within 30 days prior to the screening.&#xD;
&#xD;
          6. Prior exposure to any HSV vaccines&#xD;
&#xD;
          7. Known hypersensitive to monoclonal antibodies&#xD;
&#xD;
          8. ECG abnormalities with clinical relevance or cardiovascular diseases at screening&#xD;
&#xD;
          9. Serum creatinine &gt; 1.5 mg/dL at screening&#xD;
&#xD;
         10. AST and ALT &gt; 2.5 x ULN at screening&#xD;
&#xD;
         11. HBsAg positive or HCT antibody positive at screening&#xD;
&#xD;
         12. Syphilis RPR test positive at screening&#xD;
&#xD;
         13. TB history or documented T-spot positive, or now is under treatment of TB&#xD;
&#xD;
         14. Any other circumstances that are determined to affect the conduct or successful&#xD;
             completion of the clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Linda Shih, DVM</last_name>
    <phone>+886 36684800</phone>
    <phone_ext>3851</phone_ext>
    <email>linda.shih@unitedbiopharma.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

